Viatris (VTRS) Q4 FY25 earnings call: guidance and Q&A

Asked about the path to mid-single-digit revenue growth, confidence in 6 potential approvals, and the timing of the $400 million net savings from the strategic review.

Scott Smith outlined the growth path through base business growth, upcoming launches (Effexor, pitolisant, Spydia, low-dose estrogen patch, Ryzumvi, meloxicam), future data readouts (selatogrel, cenerimod), and capital deployment for accretive assets. Doretta Mistras detailed the savings phasing: 30% in '26, 30% in '27, 40% in '28.

“We anticipate roughly 30% in '26, an additional 30% in '27 and then the remaining approximately 40% in 2028.”

asked by Glen Santangelo · answered by Scott Smith, Theodora Mistras

Asked for a breakdown of the $650 million cost savings (COGS vs. SG&A vs. R&D), associated CapEx, and the assumed Indore bounce back in 2026 guidance.

Scott Smith stated 50% of savings from headcount reductions, the rest from COGS efficiencies, inventory management, and support structures, with R&D not a major focus for cuts. Doretta Mistras clarified that operating/COGS efficiencies are more back-end weighted. Indore recovery is assumed at less than 1% of top line, as remediation efforts and lenalidomide exclusion mitigate its impact.

“About 50% of that is coming from headcount reductions at this point in time. The other 50% is coming from COGS efficiencies, inventory management, support structures, not a lot from R&D.”

asked by Umer Raffat · answered by Scott Smith, Theodora Mistras

Asked about the magnitude of restructuring charges ($700M-$850M) relative to net savings and the initial focus for fast-acting meloxicam launch.

Doretta Mistras explained the analyst's $700M-$850M figure includes ~$250M for strategic review costs, $110M for Biocon monetization taxes, and $320M for divestiture-related costs/taxes. Corinne Le Goff stated meloxicam will focus on post-operative and operative acute pain management, targeting specialty physicians (surgeons, orthopedics, dental) with a dedicated sales force, and seeking partnerships for broader reach.

“We will focus operative -- post-operative and operative acute pain management versus nonoperative pain. We will build a specialty sales force that will target those physicians in their offices, and like surgeons, orthopedic surgeons, dental surgeries, podiatry.”

asked by Ashwani Verma · answered by Theodora Mistras, Corinne Le Goff

Asked to quantify Japan's regulatory pricing challenges, if new assets provide net growth or offset erosion, and if cost savings are from discontinued operations vs. core efficiency.

Scott Smith explained Japan's mandatory annual price decreases and structural difficulties, but new assets (Effexor GAD, pitolisant, Spydia) are expected to drive growth from 2028. Doretta Mistras noted Amitiza LOE as a 2026 headwind. Scott clarified cost savings are not from divestitures but from optimizing infrastructure post-divestitures and modernizing the core business.

“Japan is a very important market for us. Structurally, Japan is a difficult market traditionally for where we've been over the last few years as a company. There's mandatory price decreases every year on LOE products.”

asked by Leszek Sulewski · answered by Scott Smith, Theodora Mistras

Asked about expected meloxicam label (opioid sparing), FDA feedback, and BD strategy (substantial branded asset vs. smaller deals, earlier stage, verticals).

Scott Smith stated BD focus is on in-market accretive growth assets, not early pipeline, to drive growth in the next 3-4 years. Philippe Martin confirmed positive pre-NDA meeting for meloxicam, anticipating opioid-sparing language in the label (clinical section or indication section). Scott views meloxicam as a contributor into the 2030s due to exclusivity strategy.

“We're looking for in-market accretive growth assets. That's what we're really focusing on. We're not looking to acquire early pipeline.”

asked by Matthew Dellatorre · answered by Scott Smith, Philippe Martin

Asked if 2-3% underlying growth is a good proxy before pipeline/BD, and about the landscape for U.S. branded assets for BD.

Scott Smith confirmed the base business is currently growing at low single digits (1-2%, sometimes 3%), which will be enhanced by higher-growth, higher-margin assets from pipeline and BD. He noted a heating up M&A market with many interesting in-market assets available that Viatris could be good owners of.

“The way that I look at the base business right now is it's low single digits growth that we see right now. We have had -- so excluding the impact, the onetime impact of Indore, we've seen 7, 8, 9 consecutive quarters of growth. Sometimes it's 1%, 2%.”

asked by Chris Schott · answered by Scott Smith

Asked about internal innovative R&D capabilities, meloxicam exclusivity runway, and if any single product drives the $450M-$550M new revenue.

Scott Smith and Philippe Martin highlighted strong late-stage development capabilities, covering drugs from Phase I to life cycle strategy, with a focus on innovative portfolio. Scott stated meloxicam is expected to contribute into the 2030s. Doretta Mistras noted the $450M-$550M new product revenue is diversified across products (octreotide, iron ferric, iron sucrose, apixaban, paliperidone) and geographies, balanced between already approved and expected approvals.

“We've got a very strong late-stage development group led by Philippe and maybe you want to talk a little bit about those capabilities.”

asked by David Amsellem · answered by Scott Smith, Philippe Martin, Theodora Mistras, Corinne Le Goff

Asked why 2026 EBITDA only increases ~$150M despite $400M revenue increase, and for details on COGS improvement from strategic review.

Doretta Mistras explained 2026 is a stabilization year for EBITDA, with marginal gross margin decline due to mix shift (LOEs, low-margin ARV recovery) and loss of $40M TSA income. Structural expansion is expected later. Scott Smith clarified that only a 'much smaller piece' of the $650M savings comes from COGS efficiency, with 50% from headcount reductions.

“I would characterize '26 really is a stabilization year, supported by the savings realization with structural expansion really coming more visible as the savings pop in and some of our new products come into account.”

asked by Jason Gerberry · answered by Theodora Mistras, Scott Smith